Published: 10 November 2021
Author(s): Fotios Barkas, Eirini Christaki, Evangelos Liberopoulos, Maria Kosmidou, Haralampos Milionis
Issue: March 2022

Acute respiratory distress syndrome and cytokine release syndrome are the major complications of coronavirus disease 2019 (COVID-19) associated with increased mortality risk [1]. Apart from dexamethasone and probably tocilizumab in critically ill patients, there are no well-established effective therapies to treat SARS-CoV-2 infection [2,3]. Considering the noticed shortage of intensive care unit (ICU) beds and consequently the increased burden in medical wards [4], identifying additional therapeutic modalities to improve adverse outcomes and prevent ICU admission and death in this population remains a public health emergency.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.